Ostia Sciences Inc. is a biotechnology startup focused on harnessing the power of beneficial microbes to combat infectious diseases and enhance immune function. The company has made significant strides in microbiome research, particularly with the development of Salivaricin 10, which is recognized as the world's first phosphorylated antibiotic. This innovative biotherapeutic is derived from Streptococcus salivarius and is designed to provide optimal therapeutic activity against oral and respiratory tract infections. Ostia Sciences holds extensive patents for its biotherapeutic drugs, positioning itself as a leader in the creation of next-generation treatments aimed at disease prevention through microbiome-based solutions.

The company employs a cutting-edge discovery platform that identifies probiotic bacteria with drug-like properties, leading to the production of a new class of antibiotic-like molecules known as bacteriocins. This research not only focuses on the antimicrobial properties of these beneficial microbes but also their ability to modulate the immune system. Ostia Sciences is pioneering the field of microbiome therapies, with a commitment to rigorous research and development that aims to significantly improve health outcomes by leveraging the complex interactions within the human microbiome.

Canada

Welcome to Ostia Sciences, a premier microbiome solutions company that specializes in discovering novel bacterial metabolites with antibacterial, antibiofilm, and immunomodulation activities. Our goal is to isolate beneficial microbes from the human oral microbiome, human breast milk, and fermented food, which are known to be rich sources of ribosomally synthesized and post-translationally modified peptides (RiPPs) and natural products with a range of biological activities.

Ostia Sciences Inc.

Company Details